Mibrex (Rivaroxaban)

Rivaroxaban directly inhibits coagulation factor Xa, a key enzyme that converts prothrombin to thrombin. By blocking this step, the drug reduces thrombin generation and subsequent fibrin clot formation, providing anticoagulation without needing antithrombin as a cofactor.

The specific dose of Mibrex is determined by the prescribing clinician based on the patient’s indication, renal function, age, weight, and concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions and local labeling.

The safety of rivaroxaban in pregnancy or while breastfeeding has not been established. It is generally avoided in these populations unless the potential benefit justifies the potential risk, and the decision should be made by a qualified healthcare professional.

To order Mibrex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mibrex (rivaroxaban) is a direct Factor Xa inhibitor, offering fixed‑dose oral administration without routine laboratory monitoring, unlike vitamin K antagonists such as warfarin. Compared with other novel oral anticoagulants, it shares a similar efficacy profile but differs in dosing frequency and specific drug‑interaction potentials.

Mibrex should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Mibrex is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed.

The most serious risks include severe or life‑threatening bleeding such as intracranial hemorrhage, spinal or epidural hematoma, and major gastrointestinal bleeding. Patients should be educated to seek immediate medical attention for signs of unusual bleeding or bruising.

Mibrex is contraindicated in individuals with active major bleeding, severe hepatic disease associated with coagulopathy, and those who have a known hypersensitivity to rivaroxaban or any of its excipients. It should also be avoided in patients receiving other anticoagulants unless specifically directed by a healthcare professional.